Spero Therapeutics (SPRO) FCF Margin (2016 - 2026)
Spero Therapeutics posted quarterly FCF Margin of 6148.84% for Q1 2026, up 621697.0% year-on-year from N/an in Q1 2025, and up 5311.07% on a QoQ basis from 113.63% in Q4 2025.
Spero Therapeutics (SPRO) has 11 years of FCF Margin data on file, last reported at 6148.84% in Q1 2026.
- For the quarter ending Q1 2026, FCF Margin rose 621697.0% year-over-year to 6148.84%; the trailing twelve-month figure through Mar 2026 stood at 57.75% (up 13705.0% YoY), and the FY2025 full-year result was 100.19%, down 5133.0% from the prior year.
- FCF Margin for Q1 2026 stood at 6148.84%, up from 113.63% in the prior quarter.
- Across five years, FCF Margin topped out at 19635.38% in Q3 2024 and bottomed at 5763.68% in Q1 2023.
- The 5-year median for FCF Margin is 47.71% (2022), against an average of 1424.63%.
- The widest annual swing landed in 2024, when FCF Margin soared 1233493 bps; it then plunged 1931524 bps in 2025.
- A 5-year view of FCF Margin shows it stood at 265.17% in 2022, then slumped by 110 bps to 26.69% in 2023, then plunged by 190 bps to 77.34% in 2024, then soared by 247 bps to 113.63% in 2025, then surged by 5311 bps to 6148.84% in 2026.
- The last three FCF Margin figures came in at 6148.84% (Q1 2026), 113.63% (Q4 2025), and 320.14% (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -3.98% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 43.35% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 23.53% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 4.17% |
| 10 | Spero Therapeutics | 162.39 Mn | 106.26 Mn | - | 6,148.84% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6,148.84% |
| Dec 31, 2025 | 113.63% |
| Sep 30, 2025 | 320.14% |
| Jun 30, 2025 | -124.70% |
| Mar 31, 2025 | -68.13% |
| Dec 31, 2024 | -77.34% |
| Sep 30, 2024 | 19,635.38% |
| Jun 30, 2024 | -317.53% |
| Mar 31, 2024 | 64.08% |
| Dec 31, 2023 | -26.69% |
| Sep 30, 2023 | 7,300.46% |
| Jun 30, 2023 | -683.51% |
| Mar 31, 2023 | -5,763.68% |
| Dec 31, 2022 | 265.17% |
| Sep 30, 2022 | -47.71% |
| Jun 30, 2022 | -1,155.69% |
| Mar 31, 2022 | -1,364.09% |
| Dec 31, 2021 | -176.86% |
| Sep 30, 2021 | -699.44% |
| Jun 30, 2021 | -786.66% |
| Mar 31, 2021 | -212.04% |
| Sep 30, 2020 | -56,092.11% |
| Jun 30, 2020 | -1,442.44% |
| Mar 31, 2020 | -1,376.13% |
| Dec 31, 2019 | -2,513.79% |
| Sep 30, 2019 | -208.40% |
| Jun 30, 2019 | -18,144.78% |
| Mar 31, 2019 | -142.59% |
| Dec 31, 2018 | -800.30% |
| Sep 30, 2018 | -837.99% |
| Jun 30, 2018 | -1,866.31% |
| Dec 31, 2017 | -1,282.88% |
| Sep 30, 2017 | -1,761.31% |
| Jun 30, 2017 | -3,565.06% |
| Mar 31, 2017 | -4,985.00% |
| Dec 31, 2016 | 14,561.54% |